Nano

[Nano @hernanpn]

@RicardoMonrealA @Claudiashein Tienen mucho material con todo lo que hacen

[Avi 🦆 @avieu]

Este discurso de Cayetana Álvarez @cayetanaAT va a incomodar a quienes reducen la soberanía a un eslogan:

❌ No hay soberanía cuando millones viven bajo el control del crimen.
❌ No hay soberanía cuando el poder concentra y debilita contrapesos.
❌ No hay soberanía cuando se fomenta la dependencia en lugar de la libertad.

Tres enemigos internos: crimen organizado, populismo autoritario y mentalidad de dependencia. La amenaza no siempre viene de fuera. Muchas veces ya está dentro.

[Nano @hernanpn]

#miselecciónazteca Vamos México!!! @AztecaDeportes

[Nano @hernanpn]

#miselecciónazteca apoyando a la selección

[Mindy Kitei: journalist @CFSCentral]

FDA is holding up approval for Dr. Soon Shiong's Anktiva for papillary bladder cancer.

Take a minute to look at the cancer-free statistics from ChatGPT for Merck's Keytruda, which was approved for papillary bladder cancer, vs Anktiva, which has yet to be approved for papillary bladder cancer, despite the fact that Anktiva is the superior drug for this disease.

At 24 months:
Keytruda: ~30–40% disease-free. Anktiva+BCG ~52% disease-free.

At 3 years:
73% of Keytruda patients kept their bladders.
82% of Anktiva + BCG patients kept their bladders.

At 3 years:
Keytruda overall survival: ~90% Anktiva + BCG overall survival: ~96%

Dr. Makary, Dr. Bhattacharya, Sec Kennedy, please do the right thing and approve Anktiva for papillary bladder cancer now. Save more lives.

Please help spread the word & retweet this post.

@DrMakaryFDA @DrPatrick @ImmunityBio
@DrJBhattacharya @ChrisCuomo @SecKennedy
@LoriMills4CA42 @tteuscher @CarnivoreKen @julie_bush @bullishbruk @exosome @Johnincarlisle
@chrisca70578779

[Nano @hernanpn]

@DrPatrick @grok que significa esto que comenta el Dr Patrick?

[Nano @hernanpn]

@CondusefMX Gracias

[Nano @hernanpn]

@bancoplatamx ¿Podrían indicarme cómo puedo ser eliminado de su lista de llamadas? Actualmente recibo alrededor de 10 llamadas al día, lo cual resulta bastante molesto. Agradecería su apoyo para resolver esta situación. @CondusefMX

[Nano @hernanpn]

@Oshin76 @Change https://t.co/m8nyuUdnlK

[Nano @hernanpn]

@CondusefMX Para ofrecer su tarjeta plata

[Nano @hernanpn]

@IdenixH Fake

[Nano @hernanpn]

@Robbwert No compares tonterías

[Nano @hernanpn]

@bluefinsashimi @hectorcantuk

[Nano @hernanpn]

@bluefinsashimi @grok es cierto esto?

[Nano @hernanpn]

@hectorcantuk

[Groundhog day @truedat999]

🚀 $IBRX 2026 Catalyst Rocket: FDA Resub INCOMING, ASCO GU Buzz, Saudi Rollout Heating Up, Earnings Beat Potential, Major BLA Path & Global Expansion — This Dip Is Pure Setup for Explosive Leg Up 💥

Today’s dip stings after that breakout — pure profit-taking + volatility, no fresh bad news. Weak hands shaken out, but the story is stronger than ever. ~40% short float (short interest ~127M shares), borrow fees still ~9%+, low share availability, heavy call OI for gamma squeeze fuel. ANKTIVA revenue exploding: ~$113M prelim FY2025 (+700% YoY), Q4 $38M (up 20% QoQ). ~66% insider ownership (Dr. Patrick Soon-Shiong locked in) = low dilution risk, high alignment.

2026 is loaded with binary catalysts — regulatory wins, data drops, revenue ramps, global deals. Timeline based on IR, press releases, https://t.co/TwIt0ccfaa, recent updates (as of Feb 10, 2026). Estimates where needed — DYOR, NFA, biotech volatility is real.

February 2026 – Immediate Firepower

• Mid-to-late Feb: Papillary NMIBC sBLA resubmission to FDA (post-Jan 20 Type B meeting — additional data compiled, no new trial required, submit within ~30 days → expect by mid-to-late Feb). PDUFA clock starts on acceptance → huge label expansion beyond CIS!

• Feb 26–28: ASCO GU Cancers Symposium (Moscone West, SF) — ImmunityBio presenting. Expect ANKTIVA NMIBC (CIS/papillary), NSCLC (post-Saudi approval), Bioshield/lymphopenia reversal data. GU/oncology crowd = major buzz potential. SF close to SD — locals, show up!

• Ongoing Saudi/MENA momentum — Post-Jan 14, 2026 USA-Saudi Biotech Alliance Summit (inaugural, high-level deals alongside JPM HC), SFDA approvals (NSCLC + ANKTIVA combos, BCG in NMIBC), Cigalah commercialization ramp, local production, medical tourism inflows. Vision 2030 rocket fuel.

March 2026 – Earnings Catalyst
• March 2 (confirmed, before open + 4 PM ET call): Q4 2025 / FY 2025 Earnings. Spotlight on ANKTIVA quarterly ramp ($38M Q4 prelim), 2026 guidance (analysts $180M+ possible), cash ($243M end-2025), pipeline fireworks. Beat & raise = instant pump.

Q2 2026 (Apr–Jun)
• Q2: Full enrollment hit in QUILT-2.005 (BCG-naïve high-risk NMIBC, ANKTIVA + BCG vs BCG). Already >85% enrolled (ahead of schedule) — positive interim (6-mo CR 85% vs 57%, 9-mo p=0.0455) sets up BLA by year-end.
• Saudi rollout acceleration (regional office, distribution, contracts).

Q3 2026 (Jul–Sep)
• Mid-2026: Interim readouts (QUILT-3.055 NSCLC expansions, QUILT-106/3.078 CAR-NK in lymphomas/GBM — recent GBM OS not reached, lymphopenia reversed).
• Early EU/UK NMIBC sales traction (conditional approvals).
• NSCLC BLA hints / confirmatory data (ResQ201A Phase 3 ongoing).

Q4 2026 (Oct–Dec)
• Year-end: BLA submission for QUILT-2.005 (first-line BCG-naïve NMIBC) — game-changing expansion.
• Bioshield platform updates (multi-tumor lymphopenia reversal).
• Q3 Earnings (est. Nov) — revenue trajectory, cash runway, milestone wins.

Bottom line: Quiet consolidation now, but Feb–Dec is a catalyst avalanche. High short interest + gamma + real revenue growth + global approvals (Saudi firsts, EU/UK traction) + San Diego cancer innovation = massive upside setup. Recent wins (Feb 2 ResQ215B CAR-NK Phase 2 launch in indolent lymphomas, durable responses, GBM survival edge) prove the platform delivers.

Patience wins big here. Shorts are trapped, news hits could ignite covering frenzy. Who's diamond-handing through the fireworks?

Tag your $IBRX squad & drop your top catalyst below! 💪
@IdenixH @bullishbruk @Umbisam @Alhmd120690 @bigdickee @alc2022 @Berlinergy @SaiseiInvesting @petitnong_ @P_Earns24 — what's got you most hyped: papillary resub, ASCO data, or first-line BLA?

DYOR, NFA — high-risk biotech, but fundamentals rock-solid (real sales, approvals, innovation). Holding for the catalysts? Let's ride! #IBRX #Biotech #ANKTIVA @ImmunityBio @DrPatrick

[Nano @hernanpn]

$IBRX shortsqueezeeeeeeeeeeeee Ahuevo!

[Nano @hernanpn]

@FOXImpactoNFL #foximpactonfl

[Nano @hernanpn]

@FOXImpactoNFL Saludos desde CD Victoria. #foximpactonfl

[Nano @hernanpn]

@FOXImpactoNFL saludos desde Parras Coahuila

[Nano @hernanpn]

@FOXImpactoNFL saludos desde Parras Coahuila